scholarly journals The Lung Tissue Research Consortium: An extensive open database containing histological, clinical, and radiological data to study chronic lung disease

2006 ◽  
Author(s):  
Brian Bartholmai ◽  
Ronald Karwoski ◽  
Vanessa Zavaletta ◽  
Richard Robb ◽  
David Holmes
Keyword(s):  
Lung Disease ◽  
Lung Tissue ◽  
Chronic Lung Disease ◽  
Medical Image Analysis ◽  
Chronic Obstructive ◽  
Clinical Report ◽  
Diffuse Lung Disease ◽  
Obstructive Pulmonary Disease ◽  
Tissue Research ◽  
Research Consortium

The Lung Tissue Research Consortium (LTRC) is an NHLBI sponsored project which is studying histological, radiological, and clinical data on patients with Chronic Obstructive Pulmonary Disease (COPD) and idiopathic pulmonary fibrosis (IPF). At completion, over 1200 subjects will be enrolled. Each subject will have a minimum of one CT scan; however, many will likely have 3 CT scans. Each scan will have a corresponding radiological report, clinical report, and histological report. The NHLBI requires that the data collected through the LTRC be anonymized and available to independent researchers. The LTRC imaging database will be the most comprehensive database of lung CT data available to date and will serve as the basis for imaging studies of chronic lung disease for years to come. It is a significant opportunity for the medical image analysis community to investigate this database with the intent to develop new methods of registration, segmentation, and classification that may be used to diagnosis and treat patients with diffuse lung disease.

Processing of CT images for analysis of diffuse lung disease in the lung tissue research consortium

2008 ◽  
Author(s):  
Ronald A. Karwoski ◽  
Brian Bartholmai ◽  
Vanessa A. Zavaletta ◽  
David Holmes ◽  
Richard A. Robb
Keyword(s):  
Lung Disease ◽  
Lung Tissue ◽  
Ct Images ◽  
Diffuse Lung Disease ◽  
Tissue Research ◽  
Research Consortium ◽  
Diffuse Lung

Respiratory diseases and respiratory failure

2016 ◽  
Author(s):  
Professor Ann B Millar ◽  
Dr Richard Leach ◽  
Dr Rebecca Preston ◽  
Dr Richard Leach ◽  
Dr Richard Leach ◽  
...  
Keyword(s):  
Respiratory Failure ◽  
Lung Disease ◽  
Respiratory Diseases ◽  
Immunocompromised Host ◽  
Mycobacterial Infection ◽  
Sleep Apnoea ◽  
Disease Assessment ◽  
Chronic Obstructive ◽  
Diffuse Lung Disease ◽  
Obstructive Pulmonary Disease

Chapter 5 covers respiratory diseases and respiratory failure, including clinical presentations of respiratory disease, assessment of diffuse lung disease, hypoxaemia, respiratory failure, and oxygen therapy, pneumonia, mycobacterial infection, asthma, chronic obstructive pulmonary disease (COPD), lung cancer, mediastinal lesions, pneumothorax, pleural disease, asbestos-related lung disease, diffuse parenchymal (interstitial) lung disease, sarcoidosis, pulmonary hypertension, acute respiratory distress syndrome, bronchiectasis and cystic fibrosis, bronchiolitis, eosinophilic lung disease, airways obstruction, aspiration syndromes, and near-drowning, pulmonary vasculitis, the immunocompromised host, sleep apnoea, and rare pulmonary diseases.

Chronic obstructive pulmonary disease

2018 ◽  
Author(s):  
Patrick Davey ◽  
Sherif Gonem ◽  
Salman Siddiqui ◽  
David Sprigings
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Inflammatory Response ◽  
Lung Disease ◽  
Pulmonary Disease ◽  
Chronic Lung Disease ◽  
Airflow Limitation ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Chronic Inflammatory Response ◽  
Global Initiative

The Global Initiative for Chronic Lung Disease (GOLD) states that ‘chronic obstructive pulmonary disease (COPD), a common preventable and treatable disease, is characterised by persistent airflow limitation that is usually progressive and is associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles and gases. Exacerbations and comorbidities contribute to the overall severity in individual patients.’

Non-tuberculous mycobacterial lung disease in general practice

2019 ◽  
Vol 30 (9) ◽  
pp. 432-437
Author(s):  
Jacqui White ◽  
Lusha Kellgren ◽  
Marc Lipman
Keyword(s):  
Lung Disease ◽  
Chronic Lung Disease ◽  
Respiratory Infections ◽  
Signs And Symptoms ◽  
Lung Damage ◽  
Chronic Obstructive ◽  
Shared Decision ◽  
Obstructive Pulmonary Disease ◽  
Practice Nurses ◽  
Prolonged Duration

Practice nurses may be the first to notice signs and symptoms of respiratory infections, including non-tuberculous mycobacteria. As it is becoming an increasingly recognised infection, Jacqui White et al explore its epidemiology and impact on chronic lung disease Non-tuberculous mycobacteria infection is increasingly recognised as a cause of chronic lung disease. This is most often found in people with underlying lung damage, such as chronic obstructive pulmonary disease or bronchiectasis, where it may present as new, worsening or recurrent symptoms. Mycobacterial culture is central to diagnosis, though treatment is generally initiated on the basis of additional compatible symptoms and radiology. The prolonged duration of often poorly-tolerated therapy highlights the importance of patient-centred care and shared decision-making in non-tuberculous mycobacteria management.

scholarly journals Number 3: Chronic Obstructive Pulmonary Disease -- Stopping Smoking: It is Never Too Late

2000 ◽  
Vol 7 (3) ◽  
pp. 227-228
Author(s):  
Douglas MC Wilson
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Carbon Monoxide ◽  
Lung Function ◽  
Lung Disease ◽  
Pulmonary Disease ◽  
Chronic Lung Disease ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease

Smoking is the main cause of chronic obstructive pulmonary disease, and the function of the lungs in smokers deteriorates with time at a much faster rate than in nonsmokers or ex-smokers. Smokers with chronic lung disease can often function better, breathe more easily and cough less, just by stopping smoking. They require less medication (puffers, etc) and the deterioration of lung function is slowed. Within 24 h, the amount of carbon monoxide in the lungs and blood returns to normal, allowing more oxygen to supply body functions.

scholarly journals Profile and preliminary results of Iranian sub cohort chronic obstructive pulmonary disease (COPD) in Shahrekord PERSIAN cohort in southwest Iran

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Fatemeh Zeynab Kiani ◽  
Ali Ahmadi ◽  
Akbar Soleymani Babadi ◽  
Hamid Rouhi
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Lung Disease ◽  
Pulmonary Disease ◽  
Chronic Lung Disease ◽  
Occupational Exposures ◽  
Chronic Obstructive ◽  
Epidemiological Research ◽  
Obstructive Pulmonary Disease ◽  
History Of ◽  
Southwestern Iran

AbstractBackgroundChronic obstructive pulmonary disease (COPD) is a chronic and complex respiratory disorder associated with airflow limitation and increased inflammatory response of the lungs to harmful particles. The purpose of this original study was to describe the results and profile of the Shahrekord Prospective Epidemiological Research Studies in IrAN (PERSIAN) regarding COPD in southwestern Iran.MethodsThis study of asthma and respiratory diseases is a subcohort of the more extensive cohort study, i.e., Shahrekord PERSIAN cohort, a population-based prospective study on people aged 35–70 years in southwestern Iran (n = 10,075). The sample size of the subcohort was 8500 people. Annual follow-ups (person-year) of the cohort were designed to be conducted up to 2036. The instruments to collect data on various exposures were derived from the questionnaires previously developed in extensive multinational studies (occupational exposures, smoking, housing status, and fuel consumption, history of respiratory and chronic diseases, comorbidity, etc.). The Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the lower limit of normal (LLN) spirometric criteria were used to confirm COPD diagnosis.ResultsThe response rate was 93.85%. The mean age of the participants was 49.48 ± 9.32; 47.9% were male, and 52.9% were female; nearly 16% of the population was current smokers; the fuel used by most of the participants for heating the house and cooking was gas. The most common comorbidity among participants was dyslipidemia; 30% of people have three or more comorbidities. According to GOLD and LLN criteria, the Prevalence of COPD was 3.6% and 8.4%, respectively. 4.3% of the participants had a history of chronic lung disease. The group of subjects with COPD had higher mean age, fewer years of schooling, a higher percentage of smokers with a smoking history of 10 or more pack years. 4.6% of patients had a history of chronic lung disease, 17.6% had a history of asthma in childhood, and 5.2% had a family history of respiratory and pulmonary diseases.ConclusionEpidemiological research is necessary to create an appropriate framework to fight COPD. This framework requires a better description of men and women at risk of developing COPD and describing people with early-stage illnesses.

Sign in / Sign up

Export Citation Format

Share Document